Up next

DCAT Week ’17 Member Company Announcement Forum: Tracking the Pharma Manufacturing Value Chain

Senior executives from member companies of the Drug, Chemical & Associated Technologies Association (DCAT) highlighted key strategic activity, including mergers and acquisitions (M&A), post-M&A integration, and manufacturing expansions, at the DCAT Member Company Announcement Forum at DCAT Week ’17. DCAT Value Chain Insights highlights the latest developments.

Developments in Drug-Substance Manufacturing
Noramco CEO Discusses Strategy as Stand-Alone Company

Patheon Integrates Former Roche API Manufacturing Facility

BioVectra Outlines API Manufacturing Expansion

Novasep Opens New Bioconjugation Facility for ADCs

Olon Highlights Integration of Infa

CMC Biologics Updates Acquisition by AGC Asahi Glass

Developments in Drug-Product Development and Manufacturing
Mayne Pharma Specifies Timeline for $80-Million Expansion

Catalent Integrates Pharmatek and Accucaps Acquisitions

Lubrizol’s Particle Sciences Expands Manufacturing

Developments in both Drug Substance and Drug Product Manufacturing:
Siegfried CEO Outlines Five-Year Strategic Plan

CordenPharma Expands Oligonucletides and Sterile Injectables

Developments in Packaging
Datwyler Outlines $100-Million Manufacturing Expansion

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

Executive Insights: What’s Next for Novo Nordisk?

By
With new CEO Maziar Mike Doustdar taking the helm, Novo Nordisk is looking to expand its obesity franchise, with an oral version of it blockbuster weight-loss drug, Wegovy (semaglutide). Will that be the key to expanding the fortunes of the company?

Sizing Up the Blockbuster Contenders of 2025

By
What new products, recently or expected to launch in 2025, show blockbuster potential, and do their prospects still remain bright? DCAT Value Chain Insights takes an inside look at the companies & bio/pharmaceuticals rising to the top of the class.

US, EU Detail Plan for Pharmaceutical Tariffs

By
The White House and European Commission have released further details on the recently agreed-to US-EU trade deal, including further details on tariffs on pharmaceuticals. What’s the bottom line for the pharma industry?

Big Pharma & US Manufacturing Investment

By
The White House released last week a list of major capital investments in the US for manufacturing, including from the pharmaceutical industry. A roundup of investments gaining attention and other moves thus far in 2025.